Aprea Therapeutics (APRE) Expected to Announce Earnings on Tuesday

Aprea Therapeutics (NASDAQ:APRE) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. On average, analysts expect Aprea Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock opened at $0.76 on Monday. The business’s 50-day simple moving average is $0.78 and its two-hundred day simple moving average is $1.09. The company has a market cap of $8.73 million, a PE ratio of -0.38 and a beta of 1.42. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.44.

Wall Street Analyst Weigh In

A number of research firms recently commented on APRE. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price (down from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. Wedbush reduced their price target on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a research report on Tuesday, February 10th. Finally, Zacks Research upgraded shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.50.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.